Thus, our data suggest that MINDIN could enhance the activation of the Wnt/β-catenin pathway in prostate cancer cells by promoting a decrease in NHERF-1 expression at the plasma membrane, therefore releasing the membranous fraction of β-catenin. The gene discussed is SPON2; the disease is prostate cancer.